跳至主要内容
临床试验/NCT04702204
NCT04702204已完成不适用

Efficacy and Safety of Denosumab Treatment in Bisphosphonate Unresponsive Postmenopausal Osteoporotic

Nigde Omer Halisdemir University1 个研究点 分布在 1 个国家目标入组 73 人开始时间: 2020年7月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
73
试验地点
1
主要终点
Bone mineral density

研究概览

简要总结

This study, which was designed as a prospective observational study, was planned to enroll 75 female patients with postmenopausal osteoporosis who had been using bisphosphonates for more than two years and did not respond to treatment. 2 doses of denosumab were administered to the patients every 6 months. Bone mineral density of patients were measured with DEXA at the beginning and end of the study. A total of 66 patients completed the study.

At the end of the study, there was a significant improvement in the femur and lumbar total bone mineral density of the patients compared to the baseline. However, no statistically significant difference was found in terms of the frequency of new fractures.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
45 Years 至 85 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Being a woman with postmenopausal osteoporosis
  • Being between the ages of 45-85
  • Using bisphosphonate therapy for at least two years
  • Vertebral and/or Femur T score below -2.5
  • Unresponsive to bisphosphonate therapy
  • More than 2% decrease in BMD values despite using bisphosphonates and/or
  • New major fracture development during treatment

排除标准

  • Male gender
  • Being extremely thin (BMI <15) or extremely obese (BMI> 45)
  • Malignancy
  • Severe chronic liver and kidney failure
  • Chronic Steroid use
  • Having an active rheumatic disease
  • Having other secondary causes of osteoporosis (primary hyperparathyroidism etc.).

结局指标

主要结局

Bone mineral density

时间窗: 12 month

Femur and spine bone mineral density measurements of the patients at the baseline and the 12th month were performed using the Dual Energy X-ray Absorptiometry (DEXA) machine (Stratos dR 2D Fan-Beam, DMS company, France).

次要结局

  • Major Bone Fracture(12 month)

研究者

发起方
Nigde Omer Halisdemir University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ercan KAYDOK

Asst. Prof. MD.

Nigde Omer Halisdemir University

研究点 (1)

Loading locations...

相似试验